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Abstract
Background: In the present study, we determined the gene hypermethylation profiles of normal tissues adjacent
to invasive breast carcinomas and investigated whether these are associated with the gene hypermethylation
profiles of the corresponding primary breast tumors.
Methods: A quantitative methylation-specific PCR assay was used to analyze the DNA methylation status of 6
genes (DAPK, TWIST, HIN-1, RASSF1A, RARb2 and APC) in 9 normal breast tissue samples from unaffected women
and in 56 paired cancerous and normal tissue samples from breast cancer patients.
Results: Normal tissue adjacent to breast cancer displayed statistically significant differences to unrelated normal
breast tissues regarding the aberrant methylation of the RASSF1A (P = 0.03), RARb2 (P = 0.04) and APC (P = 0.04)
genes. Although methylation ratios for all genes in normal tissues from cancer patients were significantly lower
than in the cancerous tissue from the same patient (P ≤ 0.01), in general, a clear correlation was observed
between methylation ratios measured in both tissue types for all genes tested (P < 0.01). When analyzed as a
categorical variable, there was a significant concordance between methylation changes in normal tissues and in
the corresponding tumor for all genes tested but RASSF1A. Notably, in 73% of patients, at least one gene with an
identical methylation change in cancerous and normal breast tissues was observed.
Conclusions: Histologically normal breast tissues adjacent to breast tumors frequently exhibit methylation changes
in multiple genes. These methylation changes may play a role in the earliest stages of the development of breast
neoplasia.
Background
Breast cancer is the most frequently diagnosed cancer in
women worldwide http://www.cancer.org. Approxi-
mately 1.3 million women are diagnosed with breast
cancer each year. There are well-understood genetic
alterations associated with breast carcinogenesis, includ-
ing specific gene amplifications, deletions, point muta-
tions, chromosome rearrangements and aneuploidy. In
addition to these highly characterized mutations, epige-
netic alterations are key contributors to breast carcino-
genesis. The most widely studied epigenetic event in
breast cancer is the hypermethylation of CpG islands
associated with the promoter and first exon regions of
several genes [1]. Methylation of CpG islands in gene
promoter regions is thought to be especially relevant for
the silencing of important growth control genes. For
breast cancer, some of the genes reported to undergo
hypermethylation are involved in evasion of apoptosis
(DAPK, TWIST1, HOXA5), cell cycle regulation (p16,
CCND2), cell invasion and metastasis (CDH1, APC),
DNA repair (BRCA1) and cell signaling (ER and RARb2)
[2]. These epigenetic alterations occur at an early stage
in breast carcinogenesis. High levels of some hyper-
methylated genes can be detected very early, in the duc-
tal lavage and nipple aspirates of patients with ductal
carcinoma in situ and stage I tumors, with methylation
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invasive breast cancers [3].
Hitherto, there has been a focus on the biology of the
primary tumor and its immediate precursor lesions
rather than on the apparently normal epithelial cells in
which the carcinogenic sequence begins. Nevertheless,
there is a growing realization that the emergence of focal
lesions occurs in association with ‘field changes’,w h i c h
can be defined as the presence of cancer causing changes
in apparently normal tissue surrounding a neoplasm [4].
The presence of field cancerization has been described in
different cancer types, including breast cancer [5]. Pre-
vious studies have demonstrated that genetic alterations,
such as loss of heterozygosity and allelic imbalance, exist
in histologically normal breast tissues immediately adja-
cent to invasive cancers [6,7]. Recently, normal tissue
adjacent to primary breast carcinomas has been shown to
exhibit hypermethylation changes in multiple genes that
are also present in the primary tumor [8-14]. Some of the
early epigenetic changes in histologically normal tissues
adjacent to e.g. prostate or colon cancer have been
shown to be an age-related event [15-18]. However, in
breast cancer, the relationship between methylation
changes in normal breast tissues from cancer patients
and patients’ age has not yet been studied in detail.
Quantitative methylation profiling for the identification
and classification of field defects might provide an objec-
tive approach for early detection or risk assessment of
breast cancer. In fact, DNA methylation in benign breast
epithelial cells has been related to a personal history of
benign or malignant breast disease and to predicted breast
cancer risk in two independent studies [19,20]. Promoter
methylation of RASSF1A showed the greatest discrimina-
tion between benign samples from women with breast
cancer, unaffected high-risk women and unaffected low-
risk women, as defined by the Gail model [19].
In the present study, we used quantitative real-time
methylation-specific PCR (qMSP) to quantify the methyla-
tion status of 6 genes in matched normal and cancerous tis-
sues from 56 patients with invasive breast cancer: death
associated protein kinase (DAPK), TWIST, high in normal-
1( HIN-1), RAS association domain family protein 1A
(RASSF1A), retinoic acid binding receptor beta 2 (RARb2)
and adenomatous polyposis coli (APC). The purposes of
this study were: i) to measure the frequency of gene hyper-
methylation in tumor tissue, normal tissue from breast can-
cer patients and normal tissue from unaffected patients and
ii) to determine whether methylation changes in normal
tissues from breast cancer patients are associated with age.
Methods
Patients and sample collection
We collected 9 normal breast tissue samples from
patients who underwent breast reductive surgery (age
range, 25-47 years). None of these samples showed
pathological changes. In addition, we collected 56 pairs
of matched normal and breast cancer tissue samples
from patients with breast cancer (age range, 30-86 years).
Additional primary tumor characteristics were recorded
by review of pathology files and are listed in Table 1.
Tumors were histologically graded from 1 to 3 according
to the Nottingham modification of the Bloom and
Richardson histological grading scheme [21]. ER, PR and
P53 status were determined by immunohistochemistry.
HER2 status was determined according to the College of
American Pathologists (CAP) and the American Society
of Clinical Oncology (ASCO) joint guideline [22].
All samples were procured at the time of surgery, sub-
jected to an initial gross pathological examination, frozen
in liquid nitrogen and then stored in N2 at -180°C. Corre-
sponding normal tissues were procured at the most dis-
tant site from the resected specimen (distances from the
primary tumor were not routinely measured in this
Table 1 Patient characteristics
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a section adjacent to the tissue part used for DNA extrac-
tion was stained with haematoxylin and eosin for histolo-
gical confirmation of the presence or absence of cancer
cells. However, tissue sizes were inadequate to perform
tissue morphometry on these slides.
Informed consent was obtained from all patients parti-
cipating in the study. All samples were obtained from
Sint-Augustinus (Antwerp, Belgium) in accordance with
the institutional policies. All protocols were reviewed
and approved by the Ethical Committee of Sint-
Augustinus.
Extraction and sodium bisulphite conversion of DNA
DNA extractions from breast tissue samples were per-
formed using the QIAamp DNA Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s
protocol. DNA samples (200 μl) were frozen at -80°C
until use. DNA was quantified using a NanoDrop 1000
spectrophotometer (Thermo Scientific, Wilmington, DE,
USA) and 1.5 μg of DNA was sodium bisulphite-con-
verted using the EZ DNA Methylation Kit (Zymo
Research, Orange, CA, USA) according to the manufac-
turer’s instructions.
Quantitative real-time MSP
The analyte (RASSF1A, RARb2, APC, DAPK, HIN1,
TWIST1 and ACTB) quantitations were done in real-
time PCR assays using the ABI Prism 7900HT (Applied
Biosystems, Foster City, CA, USA). Methylated version
of RASSF1A, RARb2, APC, DAPK, HIN1 and TWIST1
promoter sequences were detected. ACTB was used as a
reference gene in the assay, using primers that are out-
side any CpG islands. The PCR conditions were 95°C
for 5 min, followed by 45 cycles of 95°C for 30 s, 57°C
for 30 s, and 72°C for 30 s, with a final extension cycle
of 72°C for 5 min (the annealing temperature was 51°C
instead of 57°C for the APC assay). Data were collected
at the 57°C (or 51°C) plateau.
The results were generated using the SDS 2.2 software
(Applied Biosystems, Foster City, CA, USA). The copy
numbers were calculated based on the linear regression
obtained for a standard curve of 8 to 8 × 10
5 gene copy
equivalents, using plasmid DNA containing the bisul-
phite-modified sequence of interest. CpGenome™ Uni-
versal methylated and unmethylated DNA (Millipore,
Billerica, USA) were included in each experiment as
positive and negative controls, respectively.
The amplicons generated during the amplification
process were quantified by real-time measurement of
the emitted fluorescence (fluorophore: FAM). The ratio
between the methylated marker and the independent
reference gene ACTB was calculated. This ratio was
defined as the test result (test result = copies methylated
marker/copies ACTB × 1,000).
Statistical analysis
Test results for each gene were analyzed in two ways: as
a continuous variable and as a dichotomized variable
(according to the maximal methylation ratio observed in
normal breast tissues from unaffected women). We used
Pearson’s Χ2 or, in the case of low frequencies per cell,
Fisher’s exact method to test associations between cate-
gorical variables. The Mann-Whitney U test or the Wil-
coxon signed-rank test was used to assess differences
between nonparametric distributed variables. The Kappa
statistic was used to assess the agreement between two
dichotomous variables. A two-sided P ≤ 0.05 was con-
sidered to be statistically significant. All statistical calcu-
lations were performed using SPSS, version 11.0 (SPSS
Inc, Chicago, IL, USA).
Results
Gene methylation ratios in matched normal and
cancerous breast tissue
A total of 6 genes (D A P K ,T W I S T ,H I N - 1 ,R A S S F 1 A ,
RARb2 and APC) was analyzed for promoter methyla-
tion in normal breast tissues from 9 reduction mam-
moplasty specimens and in matched normal and
cancerous tissues from 56 breast cancer patients using
qMSP. Results for all genes in all cases are presented
in Table 2.
Table 2 DNA methylation of 6 genes associated with breast carcinogenesis in normal and cancerous breast tissues.
Gene Normal tissue from
unaffected women (N = 9)
Normal tissue from cancer






DAPK 0.47 (0.00-2.51) 0.30 (0.00-690.19) 0.92 (0.00-1445.43) 0.56 0.34
TWIST 0.00 (0.00-1.78) 0.00 (0.00-388.92) 0.00 (0.00-1066.79) 0.06 0.03
HIN-1 0.00 (0.00-0.00) 0.00 (0.00-296.26) 199.46 (0.00-2627.44) 0.31 0.003
RASSF1A 0.74 (0.19-103.25) 11.15 (0.00-418.42) 348.80 (0.00-1241.21) 0.03 <0.001
RARb2 0.00 (0.00-0.00) 0.00 (0.00-183.29) 0.00 (0.00-977.59) 0.04 0.07
APC 0.00 (0.00-0.00) 0.00 (0.00-1992.07) 163.97 (0.00-4481.91) 0.04 0.004
a Comparison between normal tissues from different sources
b Comparison between normal tissue from unaffected women and cancerous tissue
Median methylation ratios and range are shown.
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breast tissue from unaffected women for 3 of the 6
genes assayed (DAPK, TWIST and RASSF1A), although
the ratios of methylation varied considerably for differ-
ent genes, from a maximal test result of approximately 2
for DAPK and TWIST to a maximal value of 103 in the
case of RASSF1A. Compared with the normal breast tis-
sues from unaffected women (N = 9), we observed
higher methylation ratios in normal breast tissues from
cancer patients (N = 56) for RASSF1A (P = 0.03, Mann
Whitney test), RARb2 (P = 0.04, Mann Whitney test)
and APC (P = 0.04, Mann Whitney test). Notably, for
the RASSF1A gene, the median methylation ratio in nor-
mal tissues from cancer patients was 15-fold higher
compared with that in normal tissues from unaffected
women. For the DAPK, TWIST and HIN-1 genes, there
were no significant differences between the normal tis-
sues from different sources. For all genes, the ratios of
methylation in cancerous tissue were higher than in
normal breast tissue from unaffected women and for 5
genes (TWIST, HIN-1, RASSF1A, APC) these differences
were statistically significant (Table 2). The methylation
ratios of different genes were not independent of each
other. Genes for which methylation ratios most closely
correlated in cancerous tissues (N = 56) were RASSF1A
and HIN-1 (r = 0.480, P < 0.001) and RASSF1A and
TWIST (r = 0.438, P = 0.001). Genes for which methyla-
tion ratios most correlated in normal tissues from can-
cer patients (N = 56) were RARb2 and APC (r = 0.502,
P < 0.001) and RASSF1A and HIN-1 (r = 0.485,
P < 0.001).
Next, we compared the methylation ratios for normal
and matched cancerous tissue for each breast cancer
patient. For all genes, the ratios of methylation in the
cancerous tissue significantly exceeded those of normal
tissue from the same patient (P ≤ 0.01, Wicoxon signed-
rank test). However, in general, a clear correlation
between methylation ratios in normal and cancerous tis-
sues could be detected. Correlation coefficients and cor-
responding values of significance were: r = 0.378 and
P=0 . 0 0 4f o rDAPK, r = 0.538 and P < 0.001 for TWIST,
r = 0.371 and P = 0.005 for HIN-1,r=0 . 4 2 8a n d
P = 0.001 for RASSF1A, and r = 0.491 and P < 0.001 for
APC.
As cut-off for scoring a sample as ‘hypermethylated’,
the maximal methylation ratio in the control group (nor-
mal breast tissues from unaffected women) was used.
The frequency of hypermethylated samples was similar in
normal and cancerous breast tissues for DAPK, TWIST
and RARb2.H o w e v e r ,f o rHIN-1, RASSF1A and APC,
cancerous breast tissues were more frequently hyper-
methylated than matched normal tissues. The methyla-
tion frequencies for cancerous and matched normal
tissues were as follows: 27% and 21% for DAPK
(P Χ
2 = 0.51), 46% and 36% for TWIST (P Χ
2 = 0.25),
59% and 11% for HIN-1 (P Χ
2 < 0.001), 77% and 18% for
RASSF1A (P Χ
2 < 0.001), 29% and 34% for RARb2 (P Χ
2
= 0.54) and 55% and 36% for APC (P Χ
2 = 0.04). Methy-
lation of at least one of the 6 genes tested was present in
87% of cancerous tissues and 62% of normal tissues (P Χ
2
= 0.002). Methylation of multiple genes (three or more
genes) was detected in 39% of cancerous tissues com-
pared with 14% of normal tissues (P Χ
2 = 0.003). The
median number of hypermethylated genes was signifi-
cantly greater for cancerous tissues than for normal tis-
sues (3 in cancerous tissues and 1 in normal tissues;
P < 0.001, Mann Whitney test) (Figure 1A).
Concordant gene methylation in matched normal and
cancerous breast tissue
For most genes, there was a fair to moderate agreement
between methylation in cancerous and matched normal
Figure 1 (A) Cumulative percentage distribution of cancerous
(black line) and normal (grey line) samples in function of
number of methylated genes. The median number of
hypermethylated genes was 3 in cancerous tissues and 1 in normal
breast tissues (P < 0.001); (B) Cumulative percentage distribution of
breast cancer tissues from patients ≥50 years (black line) and <50
years (grey line). The median number of hypermethylated genes
was 3 in cancerous tissues from patients ≥50 years and 2 in
cancerous tissues from patients <50 years (P = 0.006).
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Only RASSF1A failed to show statistically significant
concordance between the normal tissues and cancerous
tissues. Concordant methylation changes in normal and
cancerous breast tissues were present in 77% of cases
for DAPK,i n6 8 %o fc a s e sf o rTWIST, in 52% of cases
for HIN-1, in 37% of cases for RASSF1A, in 77% of cases
for RARb2 and in 66% of cases for APC.W h e nag e n e
was found hypermethylated in the primary tumor, it was
also hypermethylated in the adjacent normal tissue in
47% of cases for DAPK,i n5 4 %o fc a s e sf o rTWIST,i n
18% of cases for HIN-1, in 21% of cases for RASSF1A,
in 69% of cases for RARb2 and in 52% of cases for APC.
For DAPK, TWIST, RASSF1A, RARb2 and APC, in some
instances (2-14% of cases), a gene was found hyper-
methylated in adjacent tissue but not in the correspond-
ing primary tumor. For 41 of 56 (73%) of patients at
least one gene with an identical methylation change in
cancerous and normal breast tissues was observed.
Association between DNA methylation changes and
clinicopathological factors
Next, we investigated whether the presence of hyper-
methylated genes in normal tissues from cancer patients
was associated with clinicopathological features of the
corresponding primary tumor. The presence of at least
one hypermethylated gene in adjacent normal breast tis-
sues was significantly higher when the corresponding
primary tumors were expressing ER (P Χ
2 = 0.007) or
PR (P Χ
2 = 0.03). Furthermore, hypermethylation of
RASSF1A was more frequently present in adjacent nor-
mal breast tissues from advanced stage breast tumors
(P Χ
2 = 0.01) and hypermethylation of APC was more
frequently present in adjacent normal breast tissues
from breast tumors expressing ER (P Χ
2 = 0.04).
Association between DNA methylation changes and age
Increased DNA methylation in benign breast epithelium
has been associated with age [23]. We therefore investi-
gated DNA methylation as a function of age in normal
breast tissues from cancer patients and matched breast
tumor tissues (N = 56). The mean age of these patients
was 58 years (age range, 30-86 years). We did not inves-
tigate the association between methylation changes in
normal breast tissues from unaffected women and age
since the age distribution int h i sp o p u l a t i o nd i dn o t
allow for this analysis. For all 6 genes tested, promoter
methylation ratios in normal or cancerous breast tissues
did not correlate with patients’ age.
Next, we compared hypermethylation frequencies in
normal and cancerous tissues from women ≥50 years of
age (N = 41) and women <50 years of age (N = 15). In
normal tissues from cancer patients no differences in
hypermethylation frequencies for any of the 6 genes
tested were observed between both patient groups.
However, in cancerous tissues, hypermethylation fre-
quencies of 2 of 6 genes, DAPK (P Χ
2 = 0.005) and
HIN-1 (P Χ
2 = 0.003), were significantly higher in
patients ≥50 years of age when compared to patients
<50 years of age. Furthermore, 49% of cancerous tissues
from patients ≥50 years of age showed multiple gene
hypermethylation (three or more genes) compared to
only 13% of cancerous tissues from patients <50 years of
age (P Χ
2 =0 . 0 2 ) .A l s ot h em e d i a nn u m b e ro fh y p e r -
methylated genes was significantly higher in cancerous
tissues from patients ≥50 years of age: 3 (range, 0-6)
versus 2 (range, 0-5) (P = 0.006, Mann Whitney test)
(Figure 1B).
Discussion
Altered DNA methylation is observed in the early stages
of breast carcinogenesis. Both atypical hyperplasia and
ductal carcinoma in situ can be distinguished from nor-
mal breast tissues based on gene promoter methylation
levels [24-29,20,30,12]. Hypermethylation of tumor sup-
pressor genes has also been reported in women who are
at risk of developing breast cancer but who do not have
cancer [23,20]. This abnormal change occurs more fre-
quently in benign breast epithelium of women at high
risk for breast cancer than in women at low risk. These
findings suggest a possible cancer-predisposing role for
DNA methylation.
In the present study, we investigated aberrant methy-
lation of six genes in matched normal and cancerous tis-
sues from 56 patients with breast cancer using a qMSP
assay. Genes were selected from the literature for their
involvement in breast cancer and have been previously
shown to be affected by hypermethylation in breast can-
cer. We observed no or only low levels of methylation
in normal breast tissue samples from unaffected women.
Although sample size of normal breast tissues was
rather small, also in a previous study analyzing methyla-
tion of the APC gene promoter in 27 normal breast tis-
sues (obtained from reduction mammoplasty
specimens), we observed methylation in only three sam-
ples [31]. Despite sampling of the normal tissues at the
Table 3 Concordance between the methylation status of
cancerous and matched normal breast tissues (N = 56).
Gene T+ N+ T- N+ T- N- T+ N- Kappa P-value
DAPK 7 (13%) 5 (9%) 36 (64%) 8 (14%) 0.368 0.005
TWIST 14 (25%) 6 (11%) 24 (43%) 12 (21%) 0.344 0.008
HIN-1 6 (11%) 0 (0%) 23 (41%) 27 (48%) 0.154 0.03
RASSF1A 9 (16%) 1 (2%) 12 (21%) 34 (61%) 0.070 0.27
RARb2 11 (20%) 8 (14%) 32 (57%) 5 (9%) 0.462 <0.001
APC 16 (29%) 4 (7%) 21 (37%) 15 (27%) 0.342 0.006
Abbreviations: T, tumor; N, normal
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tion specimens, normal tissue adjacent to breast cancer
displayed statistically significant differences to unrelated
normal breast tissues regarding the aberrant methylation
of the RASSF1A, RARb2 and APC genes. Although
methylation ratios in normal tissues from cancer
patients were significantly lower than in the cancerous
tissue from the same patient, in general, a clear correla-
tion was observed between methylation ratios measured
in both tissue types for all genes tested. When analyzed
as a categorical variable, there was a statistically signifi-
cant concordance between methylation changes in nor-
mal tissues and in the corresponding tumor for all
genes tested but RASSF1A. The observed frequencies of
gene methylation in the cancerous samples were highly
concordant with previous reports http://www.pubmeth.
org. Notably, in 73% of patients, at least one gene with
an identical methylation change in cancerous and nor-
mal breast tissues was observed.
One difficulty in methylation studies is the relative
purity of the tissue samples in the cells that may be tar-
gets for CpG island methylation. Normal breast tissue
samples are largely composed of supportive stromal
cells and have actually very little epithelial cells. We
confirmed the absence of tumor cells in the normal
breast tissues on the control slides but unfortunately tis-
sue sizes were inadequate to perform extensive tissue
morphometry. We therefore cannot exclude differences
in epithelial content between normal breast tissue sam-
ples, nor the contamination by ductal carcinoma in situ.
Only a handful of other studies have assessed multiple
genes in paired cases of cancerous and adjacent normal
breast tissues. These studies reported findings similar to
ours. Lewis et al. analyzed methylation of 5 genes (APC,
RASSF1A, H-cadherin, RARb2 and CCND2)u s i n gM S P
in 17 breast tumors and matched ipsilateral normal
breast tissues [20]. Promoter hypermethylation of at
least two of these genes occurred most frequently in
breast cancer (78% of samples, N = 27) followed by nor-
mal tissue from cancer patients (40% of samples, N =
17) and at the lowest frequency in normal tissue from
unaffected women recruited from a breast cancer risk
assessment clinic (24% of samples, N = 55). For two
genes, RARb2 and APC, the differences in hypermethyla-
tion frequency between normal breast tissues from unaf-
fected women (9% and 26%, respectively), normal breast
tissues from cancer patients (32% and 33%, respectively)
and cancerous tissues (43% and 57%, respectively) were
statistically significant. Consistent with these results, our
study and the study by Bovenzi et al. reported RARb2
methylation in, respectively, 34% and 37% of normal tis-
sue samples from cancer patients (N = 8) [8]. Virmani
et al. observed a lower frequency (11%) of APC hyper-
methylation in normal tissues from resections for breast
cancer (N = 28) [13]. Fackler et al. examined six pairs of
cancerous and adjacent tissue from the surgical margins
that were histologically normal for methylation of four
genes (RASSF1A, TWIST, cyclin D2 and HIN-1)b y
qMSP [10]. The cumulative methylation levels of all
four genes within adjacent histologically normal breast
tissues were significantly lower than in the nearby carci-
noma, but significantly higher than those measured in
mammoplasty specimens (N = 9). In another study, nor-
mal tissue samples from the quadrant opposite of the
primary tumor (N = 12) showed methylation of each of
the 23 genes examined, except for CDKN2 [32]. Using
differential methylation hybridization to globally screen
CpG islands for methylation alterations in a set of
paired cancerous and normal tissues, Yan et al. uncov-
ered a group of loci frequently hypermethylated in nor-
mal tissues adjacent to breast tumors [14]. In ~70% of
the time, hypermethylation of four of these promoters
(RASSF1A, CYP26A1, KCNAB1 and SNCA) was detected
in adjacent tissues whenever these genes were found to
be hypermethylated in the primary tumor by qMSP.
Furthermore, a careful analysis of RASSF1A methylation
in normal tissues obtained at a progressively greater dis-
tance from the primary tumor suggested a gradient in
some but not all of breast samples such that the extent
of methylation was greater in the tissue within a 1 cm
circumference of the tumor compared with tissue
obtained from 2-4 cm.
Conclusions
In summary, we clearly demonstrate that histologically
normal appearing breast tissues from breast cancer
patients exhibit frequent aberrant DNA methylation
changes that are concordant with the corresponding
tumor. This hypermethylation may represent a large
field defect of preneoplastic changes that occurs early in
carcinogenesis. The fact that the normal breast tissues
lack microscopic evidence of malignancy suggests that
these changes are not transforming themselves. How-
ever, they might permit the future acquisition and accu-
mulation of other genetic and epigenetic changes that
do, in time, lead to malignancy. Similar findings have
been reported for colon [33,16,34], lung [35-37] and
prostate cancer [18]. In colon and prostate cancer, age-
related methylation changes have been suggested to
contribute to the field defect [15-18]. In our study, no
association between epigenetic alterations present in
normal breast tissues from cancer patients and patients’
age was observed. This observation does not support the
hypothesis that the observed promoter hypermethylation
of the six genes under investigation starts in the normal
breast tissue as a function of age. However, a previous
study analyzing benign breast epithelial cell samples
obtained by fine-needle aspiration biopsy have related
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age-dependent variation in methylation seems to be
gene dependent since Bean et al. did not observe an
association between IINK4a/ARF promoter methylation
in fine-needle aspiration samples from women at high
risk for development of breast cancer and patients’ age
[38].
If methylation changes do indeed occur earlier than
abnormal histologically findings and are associated with
subsequent development of breast cancer, then methyla-
tion markers in breast samples could potentially identify
women at increased risk for breast cancer who might be
good candidates for targeted screening and prevention
strategies. For women diagnosed with breast cancer, it
remains to be determined whether the identification of
methylated markers in apparently normal tissue adjacent
to tumor might be predictive of clinical outcomes, such
as local tumor recurrence.
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